Scholar Rock Holding Corporation
SRRK
Helyezés a részvények között
#3484
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to... Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
Részvényárfolyam
$40.54
Utolsó szinkronizálás: 2026-10-19
Piaci kapitalizáció
$4.94B
Változás (1 nap)
1.59%
Változás (1 év)
45.19%
Ország
US
Kereskedés Scholar Rock Holding Corporation (SRRK)
Kategória
Healthcare
EPS Scholar Rock Holding Corporation (SRRK) részvényre
EPS June 2026 dátummal, TTM: $-3.31
Scholar Rock Holding Corporation legfrissebb pénzügyi jelentései és részvényára alapján a vállalat jelenlegi EPS mutatója (TTM) $-3.31. 2023 végén a vállalat EPS mutatója $-1.99 volt, csökkenés a 2022 év EPS értékéhez, amely $-2.21 volt.
Scholar Rock Holding Corporation EPS története 2016 és 2026 között
EPS minden év végén
| Év | EPS | Változtassa meg |
|---|---|---|
| 2026 (TTM) | $-3.31 | 34.01% |
| 2024 | $-2.47 | 24.12% |
| 2023 | $-1.99 | -9.95% |
| 2022 | $-2.21 | -38.44% |
| 2021 | $-3.59 | 29.60% |
| 2020 | $-2.77 | 53.89% |
| 2019 | $-1.80 | -42.86% |
| 2018 | $-3.15 | 125.00% |
| 2017 | $-1.40 | 53.85% |
| 2016 | $-0.91 | 0.00% |
EPS hasonló cégek vagy versenytársak esetén
| Vállalat | EPS | EPS különbség | Ország |
|---|---|---|---|
| $17.32 | -623.26% |
US
|
|
| $-7.98 | 141.09% |
US
|
|
| $-5.29 | 59.82% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -938.07% |
NL
|
